Nichola Cooper, MD, FRCP, FRCPath, Imperial College London, London, UK, discusses two novel therapies which are available or in trial for patients with immune thrombocytopenia (ITP). First, Dr Cooper highlights fostamatinib, which has been recently approved by the National Institute for Health and Care Excellence (NICE) in the UK and offers a well-tolerated option for refractory patients who have failed other lines of therapy. Second, Dr Cooper discusses the neonatal Fc receptor (FcRn) inhibitor efgartigimod, which may be a viable non-immunosuppressive alternative for patients with ITP. This interview took place at the 63rd Annual Scientific Meeting of the British Society for Haematology (BSH) 2023, held in Birmingham, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
